Literature DB >> 14752294

Modulation of macrophage responsiveness to lipopolysaccharide by IRAK-1 manipulation.

Joseph Cuschieri1, Volga Bulmus, David Gourlay, Iris Garcia, Alan Hoffman, Patrick Stayton, Ronald V Maier.   

Abstract

Local activation of the macrophage by endotoxin is essential for the eradication of invasive gram-negative infections. Circulating endotoxin at lower concentrations results in immune cell activation at distant sites leading to tissue injury. Although the cellular mechanisms involved in these potentially dissimilar events are incomplete, it appears that the proximal kinase IRAK-1 plays a role. Thus, sense and antisense IRAK-1 oligonucleotides were used to determine the role IRAK-1 plays in macrophage activation by systemic (1-100 ng/mL) and local (1000 ng/mL) concentration of lipopolysaccharide (LPS) within THP-1 cells. Within the sense group, 1-1000 ng/mL of LPS within the sense group resulted in cellular activation of ERK-1/2, p38, and JNK/SAPK and the nuclear activation of NF-kappaB and AP-1. This activation was associated with proinflammatory cytokine production and cellular spreading. Systemic concentrations of LPS within the antisense group were associated with significant attenuation of intracellular signaling, cytokine production, and cellular spreading compared with the sense group. Local concentrations of LPS within the antisense group, however, were associated only with a delay in intracellular signaling, with no effect on cytokine production or cell spreading compared with the sense group. Based on these results, it appears that IRAK-1 is essential to macrophage activation at systemic, but not local, concentrations of LPS. These data suggest that redundant pathways exist that are functional at higher concentrations of LPS. Therefore, IRAK-1 appears to be the central kinase involved in the activation of the macrophage at distant sites during septic shock but is not necessary for activation in areas of local infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14752294     DOI: 10.1097/01.shk.0000111828.07309.26

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  7 in total

1.  Differential requirement of lipid rafts for FcγRIIA mediated effector activities.

Authors:  Joshua A Vieth; Moo-Kyung Kim; Xiao Qing Pan; Alan D Schreiber; Randall G Worth
Journal:  Cell Immunol       Date:  2010-08-01       Impact factor: 4.868

Review 2.  The involvement of the interleukin-1 receptor-associated kinases (IRAKs) in cellular signaling networks controlling inflammation.

Authors:  Lorna Ringwood; Liwu Li
Journal:  Cytokine       Date:  2008-01-30       Impact factor: 3.861

3.  Rapamycin Protects Sepsis-Induced Cognitive Impairment in Mouse Hippocampus by Enhancing Autophagy.

Authors:  Wenyu Liu; Jia'nan Guo; Jie Mu; Linyu Tian; Dong Zhou
Journal:  Cell Mol Neurobiol       Date:  2016-12-01       Impact factor: 5.046

4.  The Role of Lipopolysaccharide Structure in Monocyte Activation and Cytokine Secretion.

Authors:  Rebecca E Plevin; Megan Knoll; Meghan McKay; Saman Arbabi; Joseph Cuschieri
Journal:  Shock       Date:  2016-01       Impact factor: 3.454

5.  The interleukin-1 receptor-associated kinase M selectively inhibits the alternative, instead of the classical NFkappaB pathway.

Authors:  Jianmin Su; Tongli Zhang; John Tyson; Liwu Li
Journal:  J Innate Immun       Date:  2009       Impact factor: 7.349

6.  Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients.

Authors:  Kaleb M Pauley; Minoru Satoh; Annie L Chan; Michael R Bubb; Westley H Reeves; Edward Kl Chan
Journal:  Arthritis Res Ther       Date:  2008-08-29       Impact factor: 5.156

7.  Cloning of IRAK1 and its upregulation in symptomatic mandarin fish infected with ISKNV.

Authors:  Chao-Zheng Zhang; Zhi-Xin Yin; Wei He; Wei-Jian Chen; Yong-Wen Luo; Qing-Xia Lu; Shao-Ping Weng; Xiao-Qiang Yu; Jianguo He
Journal:  Biochem Biophys Res Commun       Date:  2009-03-29       Impact factor: 3.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.